Tirzepatide is a dual GIP/GLP-1 receptor agonist researched for blood sugar control and significant weight loss. By activating two metabolic pathways at once, it boosts insulin, curbs appetite, and slows digestion. In clinical research, Tirzepatide has produced greater weight reduction than most GLP-1-only compounds, along with improvements in blood sugar, cardiovascular markers, and liver fat.
Key information and effects
- Tirzepatide activates both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, and slowing gastric emptying.
- It can produce substantial weight loss by reducing appetite, increasing satiety, and improving metabolic efficiency.
- Clinical trials show greater weight reduction than most GLP-1-only medications.
- It improves blood sugar control, often leading to lower A1C levels and reduced reliance on other diabetes medications.
- Tirzepatide may improve cardiovascular markers, including blood pressure, cholesterol, and inflammation.
- Some studies suggest potential benefits for fatty liver disease (NAFLD) by reducing liver fat.
Disclaimer: This product is for laboratory research purposes only. Not for human or animal consumption. Cap colour subject to change.
Certificate of Analysis





Reviews
There are no reviews yet.